OOIR: Observatory of International Research

Papers

(The H4-Index of JAMA Oncology is 73. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
Insights Into Immune-Mediated Disease and Cancer Risk—Delivering on the Promise of UK Biobank Big Data	1296
What Is the Optimal Treatment for Vulnerable Older Women With Ovarian Cancer?	452
Malignant Pericardial Effusion, or Fluid Around the Heart Due to Cancer	450
Information Blocking and Oncology	359
Analysis of Quality-of-Life Outcomes by Drug Class in Cancer Clinical Trials—Reply	312
JAMA Oncology	260
Induction Chemotherapy for Advanced Nasopharyngeal Carcinoma—Is This the New Standard of Care?	259
Radiation-Associated Secondary Cancer in Patients With Breast Cancer Harboring TP53 Germline Variants	252
Concerns Regarding the Utility of High-Risk Pancreatic Cancer Surveillance—Reply	250
Sexual Rehabilitation Needs of Gay and Bisexual Men With Cancer	238
Overall Survival in the CAIRO5 Clinical Trial	232
Active Cellular Immunotherapy in the Desert of Advanced Prostate Cancer	228
Audit of Data Sharing by Pharmaceutical Companies for Anticancer Medicines Approved by the US Food and Drug Administration	228
The Inclusion of Women in Global Oncology Drug Trials Over the Past 20 Years	214
Stargazers	212
Biomarker Analysis of Vistusertib Plus Paclitaxel Regimen	206
Errors in Key Points and Abstract	195
Error in Text	186
Piercing the Fog	181
The Implications of the Supreme Court Decision to Overturn Roe v Wade for Women With Pregnancy-Associated Cancers	180
The Multidisciplinary Cancer Conference	170
Immunotherapy in Prepatients—Preventing or Promoting a Malignant Transformation?	169
Association of Body Mass Index With the Safety Profile of Nivolumab With or Without Ipilimumab	161
Allogeneic CD19/CD22 CAR T-Cell Therapy for B-Cell Acute Lymphoblastic Leukemia	158
Diversity Trends by Sex and Underrepresented in Medicine Status Among US Radiation and Medical Oncology Faculty Over 5 Decades	147

Transplant-Free Approach in Relapsed Hodgkin Lymphoma in Children, Adolescents, and Young Adults	142
Methodology Concerns Regarding Claims Data Studies in Transgender Health—Reply	141
Firearm Safety for Patients Diagnosed With Cancer—A Role in Suicide Prevention	140
Assessment of a Genomic Assay in Patients With ERBB2-Positive Breast Cancer Following Neoadjuvant Trastuzumab-Based Chemotherapy With or Without Pertuzumab	133
The Global Economic Cost of Cancer—Estimating It Is Just the First Step!	130
Systemic Anticancer Therapy and Overall Survival in Patients With Very Advanced Solid Tumors	127
Long-term Effect of Machine Learning–Triggered Behavioral Nudges on Serious Illness Conversations and End-of-Life Outcomes Among Patients With Cancer	124
Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Non–Small Cell Lung Cancer	124
Association of Modifiable Risk Factors With Early Discontinuation of Adjuvant Endocrine Therapy	122
Association Between Overall Survival and the Tendency for Cancer Programs to Administer Neoadjuvant Chemotherapy for Patients With Advanced Ovarian Cancer	120
Human Leukocyte Antigen Class I Antigen-Processing Machinery Upregulation by Anticancer Therapies in the Era of Checkpoint Inhibitors	118
High-risk Medulloblastoma—Balancing the High Stakes of Molecular Profiling to Enhance Treatment Responsivity	118
Natural Language Processing–Assessed Unmet Medical and Social Needs in Cancer Crowdfunding Stories	117
Use of Participation to Prevalence Ratio for Evaluating the Representation Status of Women in Oncology Clinical Trials—Reply	111
The Most Difficult Lesson From Cancer Just Might Be Its Most Valuable	110
SARS-CoV-2 Infections, Hospitalizations, and Mortality in Vaccinated Patients With Cancer in the US	109
Association of 5α-Reductase Inhibitor Use With Prostate Cancer–Specific Mortality—Reply	107
What Is the Optimal Treatment for Vulnerable Older Women With Ovarian Cancer?	107
Internal Mammary Nodal Irradiation Debate for Node-Positive Breast Cancer—Has the Needle Moved?—Reply	105
Population-Based Prostate Cancer Screening With Magnetic Resonance Imaging or Ultrasonography—The IP1-PROSTAGRAM Study—Reply	105
Coding Errors in Study of Eligibility for Lung Cancer Screening	103
Is Colorectal Cancer Screening Absolutely Beneficial for Older Adults?	98
Errors in Reported Outcomes and Table	96
Is Appendiceal Cancer a Lynch Syndrome–Associated Cancer?	96
The SOUND Randomized Clinical Trial Results	95
Results of the TARGET-TP Randomized Clinical Trial	95
Variability in COVID-19 Vaccine Response Among People With Cancer	92
Trauma	92
JAMA Oncology	91
An Atypical Rash on the Chest	91
Immunotherapy Before Chemoradiotherapy—More Is Better?	89
Alteration of the Tumor Microenvironment With Intratumoral Dendritic Cells Before Chemotherapy in ERBB2 Breast Cancer	88
The Oncologic Drugs Advisory Committee Votes of April 2021—Implications for the Fate of Accelerated Approval	88
Undiagnosed Cancer Cases in the US During the First 10 Months of the COVID-19 Pandemic	87
Nivolumab and Ipilimumab Combination Treatment in Advanced Ovarian and Endometrial Clear Cell Cancers	84
Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent	84
Early Readout on Overall Survival of Patients With Melanoma Treated With Immunotherapy Using a Novel Imaging Analysis	83
Caution Regarding Assessment of Toxic Effects and Survival in Treatment De-escalation With Radiotherapy vs Transoral Surgery for Human Papillomavirus–Associated Oropharyngeal Cancer	82
Unplanned Hospitalization Prediction During Chemoradiotherapy Via Machine Learning Classifiers—Reply	82
Assessment of Prostate Cancer Treatment Among Black and White Patients During the COVID-19 Pandemic	80
Steroid Dose and Duration, Immortal Time Bias, and Survival After High-grade Immune-Related Adverse Events—Reply	80
Disparities in Trends of Gastroenteropancreatic Neuroendocrine Tumor Incidence	80
Unwinding of Medicaid Continuous Enrollment Exposes Millions to Disrupted Care—“Be Kind, Rewind”	79
Accelerated Approval Is Not Conditional Approval	78
Shifting Toward Precision Oncology in SCLC Treatment	78
Effect of Postoperative Radiotherapy for Patients With pIIIA-N2 Non–Small Cell Lung Cancer After Complete Resection and Adjuvant Chemotherapy	77
Effect of Supine vs Prone Breast Radiotherapy on Acute Toxic Effects of the Skin Among Women With Large Breast Size	76
Evaluation of Alisertib Alone or Combined With Fulvestrant in Patients With Endocrine-Resistant Advanced Breast Cancer	75
Trends in the Characteristics, Treatment, and Outcomes of Rectal Adenocarcinoma in the US From 2004 to 2019	73
Assessment of Racial Disparity in Survival Outcomes for Early Hormone Receptor–Positive Breast Cancer After Adjusting for Insurance Status and Neighborhood Deprivation	73

Clinical Trial Diversity—Will We Know It When We See It?	73
Noninferiority of Hypofractionated vs Conventional Postprostatectomy Radiotherapy for Genitourinary and Gastrointestinal Symptoms	73